Q-omics provides the consensus-scored PDILT profile across patient tissues and cancer cell-line models. PDILT expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PDILT is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PDILT RNA expression shows 6,170 significant pathway-activity associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KIRC, and KIRP as cancer lineages where PDILT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDILT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDILT survival associations across molecular data types. PDILT RNA expression shows survival associations in the most cancer types (14), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDILT RNA expression–survival associations across cancer types. High PDILT expression shows unfavorable associations in UCEC, CESC, SKCM, CHOL and COAD, but favorable associations in GBM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PDILT RNA expression.
This table summarizes PDILT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PDILT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDILT shows lower tumor expression in KIRC, KICH, KIRP, STAD, PAAD and COAD. The KIRC box plot shows higher PDILT RNA expression in normal versus tumor tissue (log2 FC = −0.453, t-test p < 0.001).
This table shows molecular features associated with PDILT in patient tissues and cancer cell lines. In patient samples, PDILT shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PDILT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
